No increased cardiovascular risk detected for new diabetes medication
Trial by BWH researchers is the first to report on the cardiovascular safety of widely prescribed glucose-lowering drug
2015-06-08
(Press-News.org) An international, multidisciplinary team including investigators from Brigham and Women's Hospital (BWH) has found that lixisenatide, a member of a class of glucose-lowering drugs frequently prescribed in Europe to patients with diabetes, did not increase risk of cardiovascular events including heart failure. These results - the first to be reported on the cardiovascular safety of a glucagon-like peptide 1 (GLP-1) receptor agonist - were presented today at the American Diabetes Association's 75th Scientific Sessions.
"There are a large number of patients around the world who take this class of agents to help manage their glucose -based on our results patients and their healthcare providers should be reassured of the cardiovascular safety of lixisenatide even if they are at high risk for heart-related problems," said Marc Pfeffer, MD, PhD, a member of the Cardiovascular Medicine Division at BWH, professor at Harvard Medical School and principal investigator for the ELIXA (Evaluation of LIXisenatide in Acute Coronary Syndrome) trial.
Patients with type 2 diabetes are at high risk for developing cardiovascular disease and some glucose-lowering drugs have been associated with an additional increase risk of adverse cardiovascular effects. These observations prompted the US Food and Drug Administration and the European Medicines Agency to establish guidelines for clinical trials to ensure that new therapies do not put type 2 diabetes patients at increased cardiovascular risk.
In the ELIXA study, researchers enrolled more than 6,000 type 2 diabetes patients from 49 countries who had recently recovered from a heart attack or other acute coronary event to evaluate the effects of lixisenatide on a population at high risk of a cardiovascular event. The large, double-blind, placebo-controlled study measured multiple outcomes, including cardiovascular death, heart attack, stroke, hospitalization for chest pain and heart failure.
Overall, the research team found that the drug had a neutral effect on risk of cardiovascular problems - that is, it neither increased nor decreased risk, all within the limits of the FDA's safety guidelines. In addition, lixisenatide provided a modest benefit in terms of weight gain, and no increase in cancers or pancreatitis.
"ELIXA provides data showing that this treatment can be used in a safe manner without worsening cardiovascular prognosis of patients with type 2 diabetes, even among the highest risk population - those with a pre-existing history of heart failure," said Eldrin Lewis, MD MPH, a physician in the Cardiovascular Medicine Division at BWH and an associate professor at Harvard Medical School.
For researchers at the Brigham and their collaborators, the results of the study are just the beginning: the data collected from 6,000 patients all over the world will be used for future analysis to better understand the prognosis for patients with diabetes.
"We now have an expansive data set from patients with type 2 diabetes from around the globe, and we look forward to collaborating with our international ELIXA co-investigators to further explore data about cardiovascular outcomes in this patient population," said Brian Claggett, PhD, of BWH's Cardiovascular Medicine Division.
INFORMATION:
This research was supported by Sanofi.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in Massachusetts and employs nearly 15,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $650 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH continually pushes the boundaries of medicine, including building on its legacy in transplantation by performing a partial face transplant in 2009 and the nation's first full face transplant in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials group. For more information, resources and to follow us on social media, please visit BWH's online newsroom.
ELSE PRESS RELEASES FROM THIS DATE:
2015-06-08
ORANGE, Calif. -- In a study just published by researchers at Chapman University, findings showed that greater life satisfaction in adults older than 50 years of age is related to a reduced risk of mortality. The researchers also found that variability in life satisfaction across time increases risk of mortality, but only among less satisfied people. The study involved nearly 4,500 participants who were followed for up to nine years.
'Although life satisfaction is typically considered relatively consistent across time, it may change in response to life circumstances ...
2015-06-08
Glenview, Ill. (June 8, 2015)-- A Canadian study published in the June issue of the journal CHEST found weight loss reduced asthma severity as measured by airway hyperresponsiveness (AHR) in obese adults. The incidence of asthma is 1.47 times higher in obese people than nonobese people, and a three-unit increase in body mass index is associated with a 35% increase in the risk of asthma. The study supports the active treatment of comorbid obesity in individuals with asthma.
The study, the first of its kind to rely on appropriate physiologic tests as diagnostic criteria ...
2015-06-08
Baltimore, Md. (Embargoed until 12:30 p.m. EDT, June 8, 2015) - Imaging lung cancer requires both precision and innovation. With this aim, researchers have developed a technique for clinical positron emission tomography (PET) imaging that creates advanced whole-body parametric maps, which allow quantitative evaluation of tumors and metastases throughout the body, according to research announced at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Scientists have developed a novel agent for cancer imaging that seeks and attaches ...
2015-06-08
Baltimore, Md. (Embargoed until 12:30 p.m. EDT, June 8, 2015) - A first-in-human study revealed at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows how a powerful new drug finds and attaches itself to the ovarian and prostate cancer cells for both imaging and personalized cancer treatment.
The targeted aspect of the imaging agent, called I-124 PEG-AVP0458, is a small protein (avibody) linked to polyethylene glycol (PEG) chains. The drug compound is then labeled with the radionuclide iodine-124. Drugs like PEG-AVP0458 are ...
2015-06-08
Baltimore, Md. (Embargoed until 12:30 p.m. EDT, June 8, 2015) - Non-Hodgkin lymphoma (NHL), a potentially devastating cancer of the blood and immune system, can range from relatively easy to treat to very aggressive. For more aggressive cases, post-treatment surveillance with molecular imaging could mean the early start of a new, life-saving treatment, say researchers presenting during the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
NHL is the fifth most prevalent cancer in America, according to lead author Mehdi Taghipour, MD, ...
2015-06-08
Baltimore, Md. (embargoed until 12:30 p.m. EDT, June 8, 2015) - Research presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows how a new molecular imaging agent finds prostate cancer that has spread to other tissues by locking in on an enzyme called prostate specific membrane antigen (PSMA), associated with prostate cancer.
"To date, conventional imaging is limited in detecting prostate cancer metastasis accurately and measurably," said Neeta Pandit-Taskar, MD, co-author of the study and a researcher at Memorial Sloan ...
2015-06-08
A recently developed tool can accurately predict the risk of death for patients within 1 year after admission to hospital using routinely collected data, reports a study in CMAJ (Canadian Medical Association Journal).
"An accurate assessment of risk of death, particularly if that risk is high, could motivate and inform discussions between patients and physicians regarding goals of care," states Dr. Carl van Walraven, a researcher at the Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, who developed the tool.
Researchers in Canada and the United States ...
2015-06-08
Baltimore, Md. -- Scientists are taking medical imaging research and drug discovery to a new level by developing a molecular imaging system that combines several advanced technologies for all-in-one imaging of both tissue models and live subjects, say presenters at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
The preclinical and intra-vital molecular imaging system houses a window for tissue observation in addition to a larger imaging chamber. Together they are being used to peer into the microenvironment of tumors and other ...
2015-06-08
Baltimore, Md. (Embargoed until 12:30 p.m., June 8, 2015) - The origin of cancer is often obscured by metastases--tumors that have already spread to other tissues. This is especially the case for neuroendocrine tumors (NETs), a malignancy of nerve cells scattered throughout various organ systems that are sensitive to the signaling of neurotransmitters and hormones. An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). ...
2015-06-08
Baltimore, Md. -- A relatively new biomarker called prostate-specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
'We have shown in this proof-of-concept study that PSMA could serve as a biomarker for MR-based molecular imaging due to its high concentration within target cells, limited expression within non-targeted ...
LAST 30 PRESS RELEASES:
[Press-News.org] No increased cardiovascular risk detected for new diabetes medication
Trial by BWH researchers is the first to report on the cardiovascular safety of widely prescribed glucose-lowering drug
